ImmunoCellular Therapeutics (IMUC) Prices 47M Share Stock Offering for Proceeds of $7.4M
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
ImmunoCellular Therapeutics, Ltd. (NYSE: IMUC) announced the pricing of an underwritten public offering of 47,000,000 shares of its common stock and base warrants to purchase up to 35,250,000 shares of its common stock at a public offering price of $0.16 per share and related base warrant, for total expected gross proceeds to ImmunoCellular of approximately $7.4 million, before deducting underwriting discounts, commissions, and other offering expenses. The base warrants have an exercise price of $0.1921 per share of common stock, are exercisable immediately and will expire five years from the date of issuance. Additionally, ImmunoCellular has granted the underwriters a 45-day option to purchase up to an additional 7,050,000 shares of its common stock and/or base warrants to purchase 5,287,500 shares of its common stock.
As a component of the offering, ImmunoCellular is offering pre-funded warrants in lieu of common stock to certain investors at the per share public offering price for the common stock and related base warrant, less the $0.01 per share exercise price for each such pre-funded warrant.
The shares of common stock are currently listed on the NYSE MKT under the ticker symbol "IMUC." ImmunoCellular has applied to list the base warrants on the NYSE MKT and expects trading to begin following their issuance at closing under the ticker symbol "IMUCWS." The offering is expected to close on or about August 12, 2016, subject to the satisfaction of customary closing conditions.
Maxim Group LLC is acting as sole book-running manager for the offering. Laidlaw & Company (UK) Ltd. is acting as lead manager.
ImmunoCellular intends to use the net proceeds of this offering to continue enrollment in its phase 3 clinical trial of ICT-107, to complete phase 1 development of ICT-121, to continue its T cell research program and for working capital and general corporate purposes. A portion of the net proceeds may be used to acquire additional technologies.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission (SEC) on August 4, 2016, and a post-effective amendment thereto was declared effective by the SEC on August 8, 2016, which may be obtained at the SEC's website at http://www.sec.gov. Copies of the final prospectus relating to this offering, when available, also may be obtained from Maxim Group LLC, 405 Lexington Avenue, 2nd Floor, New York, NY 10174, or by telephone at 212-895-3745.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Herbalife (HLF) Provides Q4, FY17 Guidance in Memorandum for $1.325B Credit Facility; Lowers FY17 Sales Guidance
- Zynerba Pharma (ZYNE) Prices 2.8M Shares at $18 Per Share
- EXCO Resources (XCO) Announces Receipt of NYSE Continued Listing Standard Notice
Create E-mail Alert Related CategoriesCorporate News, Equity Offerings
Related EntitiesMaxim Group, Definitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!